Celldex second quarter net loss increases to $10.

G&A expenditure decreased by $0.8 million to $4.6 million in 2011 when compared with G&A expense of $5.4 million in the first half a year of 2010, due to reduced stock-based compensation primarily, patent and other professional solutions expenses incurred in 2011. The $1.june 30 2 million decrease in amortization expense for the six months finished, 2011 was primarily because of the amortization this year 2010 of intangible property acquired in connection with the CuraGen acquisition.Led by principal investigator Ronald J. Wapner, MD, professor and vice chair for study at CUMC's Department of Obstetrics and Gynecology and director of reproductive genetics at NewYork-Presbyterian Hospital/Columbia, the research is the next stage of a project to advance clinicians' capability to diagnose in utero circumstances such as developmental delays, structural abnormalities, and treatable or life-threatening illnesses. ‘Parents of kids found to have a genetic variance need a better understanding of what this means.